Format

Send to

Choose Destination
Insights Imaging. 2013 Aug;4(4):509-12. doi: 10.1007/s13244-013-0262-8. Epub 2013 Jun 12.

Parenteral ferumoxytol interaction with magnetic resonance imaging: a case report, review of the literature and advisory warning.

Author information

1
The Ottawa Hospital, The University of Ottawa, 1053 Carling Avenue, Ottawa, Ontario, Canada, K1Y 4E9, nschieda@toh.on.ca.

Abstract

BACKGROUND:

Ferumoxytol is a safe and effective parenteral therapy used for the treatment of iron deficiency anaemia that has recently been approved for use in North America and in Europe.

METHODS:

Ferumoxytol consists of a superparamagnetic iron oxide (SPIO) core, which causes T1, T2 and T2* shortening effects, and a carbohydrate shell, which results in a prolonged intravascular half life.

RESULTS:

These properties are under-reported and not well recognised. They can interfere with MRI interpretation, potentially masking enhancement and rendering examinations non-diagnostic or simulating pathologic disease states. Both radiologists and non-radiologist physicians must consider the potential interaction of ferumoxytol with MRI when interpreting and prescribing MRI examinations in their patients.

MAIN MESSAGES:

• Ferumoxytol has recently been approved for the treatment of iron deficiency anaemia. • Ferumoxytol is a small iron oxide particle with prolonged intravascular half life and T1, T2 and T2* shortening effects. • Administration of ferumoxytol can mask enhancement, rendering MRI studies potentially non-diagnostic. • Ferumoxytol can mimic diseases such as haemosiderosis, haemochromatosis and superficial siderosis. • Ferumoxytol interactions with MRI must be recognised by radiologists and non-radiologist physicians.

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center